Loading...
•
Mar 31, 2024
EyePoint Pharmaceuticals Q1 2024 Earnings Report
Announced first quarter 2024 financial results and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $11.7 million for the first quarter ended March 31, 2024, compared to $7.7 million for the same period in 2023. The company's operating expenses totaled $45.0 million, and net loss was $29.3 million, or ($0.55) per share. Cash and investments totaled $299.3 million as of March 31, 2024.
The company is on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024.
Cash and investments were $299 million as of March 31, 2024, providing a cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026.
The company plans to assess the full twelve-month study results of the Phase 2 PAVIA clinical trial of DURAVYU™ in non-proliferative diabetic retinopathy (NPDR) to evaluate the path forward for DURAVYU as a potential treatment for NPDR.
EyePoint plans to host an R&D Day on June 26, 2024, in New York City.
Revenue by Segment
Forward Guidance
The company expects its cash, cash equivalents, and investments as of March 31, 2024, will enable it to fund operations through topline data for the planned Phase 3 clinical trials of DURAVYU for wet AMD in 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...